# PDUFA calendar: FDA target action dates in the next 30 days

Canonical: https://sec-api.dev/pdufa-calendar

> 9 PDUFA target action dates fall between November 16, 2026 and December 16, 2026. The next is Savara Inc (SVRA) on November 22, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in the next 30 days?

PDUFA dates in the next 30 days: Savara Inc (SVRA) on November 22, 2026; deramiocel (CAPR) on November 22, 2026; venglustat (SNY) on November 25, 2026; ribitol (BBIO) on November 27, 2026; bezuclastinib (COGT) on November 30, 2026; povetacicept (VRTX) on November 30, 2026; and 3 more. [Calendar and source filings](https://sec-api.dev/pdufa-calendar)

Source: SEC Form 10-Q, accession 0001193125-26-453535, https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa-calendar#answer

## Next 30 days

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 22, 2026 | [Savara Inc PDUFA date](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | scheduled | "The FDA determined that the Company's responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm)) |
| November 22, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | rare diseases, today | scheduled | "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm)) |
| November 25, 2026 | [Venglustat PDUFA date](https://sec-api.dev/pdufa/venglustat) | SNY |  | scheduled | "The target action date for the FDA decision is November 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm)) |
| November 27, 2026 | [Ribitol PDUFA date](https://sec-api.dev/pdufa/ribitol) | BBIO |  | scheduled | "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| November 30, 2026 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 30, 2026 | [Povetacicept PDUFA date](https://sec-api.dev/pdufa/povetacicept) | VRTX | immunoglobulin A nephropathy | scheduled | "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| Dec 2026 | [Orencia (abatacept) PDUFA date](https://sec-api.dev/pdufa/abatacept) | RDY |  | scheduled | "As we speak today, the goal date for abatacept is in mid-December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000536/rdy0931_ex99-1.htm)) |
| December 3, 2026 | [Zanzalintinib PDUFA date](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | previously treated metastatic colorectal cancer | scheduled | ""Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| December 12, 2026 | [Imsidolimab PDUFA date](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | scheduled | "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |

## By month

- [November 2026](https://sec-api.dev/fda-calendar/2026-11): 6 PDUFA dates
- [December 2026](https://sec-api.dev/fda-calendar/2026-12): 8 PDUFA dates
- [January 2027](https://sec-api.dev/fda-calendar/2027-01): 8 PDUFA dates
- [February 2027](https://sec-api.dev/fda-calendar/2027-02): 11 PDUFA dates
- [March 2027](https://sec-api.dev/fda-calendar/2027-03): 8 PDUFA dates
- [April 2027](https://sec-api.dev/fda-calendar/2027-04): 8 PDUFA dates
- [May 2027](https://sec-api.dev/fda-calendar/2027-05): 7 PDUFA dates
- [June 2027](https://sec-api.dev/fda-calendar/2027-06): 5 PDUFA dates
- [November 2027](https://sec-api.dev/fda-calendar/2027-11): 1 PDUFA date

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA calendar: FDA target action dates in the next 30 days." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa-calendar

```bibtex
@misc{secapidev_pdufa_calendar_20261116,
  title        = {PDUFA calendar: FDA target action dates in the next 30 days},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa-calendar}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_calendar_20261116","title":"PDUFA calendar: FDA target action dates in the next 30 days","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa-calendar","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
